Zolgensma First To Be Subject To New German Data Collection Rules
Pricing And Reimbursement Body Sets Out New Process
Executive Summary
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
You may also be interested in...
Germany To Increase Data Requirements For Pricing Orphan And Other Drugs
A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.